AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9809934
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of wall motion and MCE assessment
Trial: 7661162
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with bismuth, metronidazole, and tetracycline (BMT) for 1 week
Trial: 7661162
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with sucralfate, metronidazole, and tetracycline (SMT) for 1 week
Trial: 6990320
Drug: Co-trimazine (sulphadiazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimazine (sulphadiazine 410 mg and trimethoprim 90 mg 12-hourly)
Trial: 6990320
Drug: Co-trimoxazole (sulphamethoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (sulphamethoxazole 800 mg and trimethoprim 160 mg 12-hourly)
Trial: 6990320
Drug: Sulphamethizole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphamethizole (1 g 8-hourly)
Trial: 29492753
Drug: App+Reminder (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App+Reminder (weekly reminders to use app)
Trial: 25902387
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen (IVA) preoperatively
Trial: 25902387
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen (IVA) within 30 minutes of surgery
Trial: 22889730
Drug: Protein supplementation
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplementation (15 g protein at breakfast and lunch)
Trial: 15244109
Drug: Stressen (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stressen (twice daily for 30 days)
Trial: 2532102
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin injection treatment
Trial: 2532102
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (CSII and injections)
Trial: 59150
Drug: Quinine sulphate
RxNorm normalized name: Quinine sulphate
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine sulphate 320 mg
Trial: 31221872
Drug: Financial incentive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Financial incentive (a chance to get shopping points) for increasing daily steps
Trial: 27269410
Drug: Intravenous ferrous
RxNorm normalized name: Ferrous Fumarate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferrous sucrose (up to three calculated replacement doses)
Trial: 27269410
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulphate (150 mg twice daily for six weeks)
Trial: 25831420
Drug: 9-valent human
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent human papillomavirus (9vHPV) vaccine administered concomitantly with REPEVAX (diphtheria, tetanus, pertussis, and poliomyelitis vaccines)
Trial: 25831420
Drug: REPEVAX (diphtheria,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REPEVAX (diphtheria, tetanus, pertussis, and poliomyelitis vaccines)
Trial: 25831420
Drug: Nonconcomitant vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonconcomitant vaccination group (REPEVAX administered at month 1)
Trial: 23724225
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg inhaled budesonide
Trial: 23724225
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg prednisolone orally daily
Trial: 23724225
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (for budesonide trial)
Trial: 11110928
Drug: Pulse-spray thrombolysis
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse-spray thrombolysis
Trial: 11110928
Drug: Thrombus treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombus treatment time for thrombectomy
Trial: 11110928
Drug: Thrombus treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombus treatment time for thrombolysis
Trial: 2581324
Drug: Indomethacin 25
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 25 mg 3 times a day
Trial: 27612525
Drug: Corticosteroids (methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (methylprednisolone 32 mg)
Trial: 27612525
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (methylprednisolone 32 mg and meloxicam 15 mg)
Trial: 27612525
Drug: NSAIDs (meloxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (meloxicam 15 mg)
Trial: 21696732
Drug: 5-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of amoxicillin clavulanate
Trial: 18224344
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme (ACE) inhibitors for mild IgA nephropathy
Trial: 18224344
Drug: Steroids for
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids for severe IgA nephropathy
Trial: 17194243
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (Cr) supplementation at a dose of 0.3 g.kg(‐1) for the initial 7 days and 0.03 g.kg(‐1) for subsequent 9 weeks
Trial: 17194243
Drug: Placebo (Pl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Pl) at a dose of 0.3 g.kg(‐1) for the initial 7 days and 0.03 g.kg(‐1) for subsequent 9 weeks
Trial: 14989126
Drug: Multimodality treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodality treatment including IORT
Trial: 14989126
Drug: Multimodality treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodality treatment without IORT
Trial: 8756734
Drug: Clostilbegyt treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clostilbegyt treatment (50 mg daily for 240 days)
Trial: 1818002
Drug: Gallopamil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil (50 mcg/Kg over 5 min)
Trial: 27262086
Drug: Sarcosine (2g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarcosine (2g daily)
Trial: 19188900
Drug: Non-specific oral
RxNorm normalized name: Tavist Non-Sedating Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-specific oral advice to increase physical activity
Trial: 15799006
Drug: Hebervital (formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hebervital (formulation A)
Trial: 15799006
Drug: Neupogen (formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neupogen (formulation B)
Trial: 12002769
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus granulocyte colony-stimulating factor
Trial: 12002769
Drug: Prior chemotherapy
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior chemotherapy courses
Trial: 12002769
Drug: Disease status
RxNorm normalized name: Statuss Green Reformulated Jan 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease status or mobilizing regimen dose
Trial: 6136432
Drug: morphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine (10 mg)/droperidol (2.5 mg)/atropine (0.3 mg)
Trial: 6136432
Drug: pethidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pethidine (100 mg)/droperidol (2.5 mg)/atropine (0.3 mg)
Trial: 6136432
Drug: pethidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pethidine (100 mg)/droperidol (2.5 mg)
Trial: 31727024
Drug: Nivolumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab + 12-weekly ipilimumab
Trial: 31727024
Drug: Nivolumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab + 3-weekly ipilimumab
Trial: 25934864
Drug: (−)‐epicatechin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (−)‐epicatechin (100 mg/d)
Trial: 25934864
Drug: quercetin‐3‐glucoside (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quercetin‐3‐glucoside (160 mg/d)
Trial: 21195961
Drug: Warmed saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed saline solution (37.5°C)
Trial: 21195961
Drug: Room-temperature saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room-temperature saline solution
Trial: 18844082
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg soy isoflavone and 440 mg Ca and 100 IU VD supplement/d (n = 26)
Trial: 18844082
Drug: 440 mg
RxNorm normalized name: placebo 440 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 440 mg Ca and 100 IU VD supplement/d (n = 26)
Trial: 16580392
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH‐a) therapy for 3 months
Trial: 16580392
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH‐a) therapy
Trial: 15486831
Drug: Tafenoquine, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine, 300 mg per day for 7 days (n=18)
Trial: 15486831
Drug: Tafenoquine, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine, 600 mg per day for 3 days (n=19)
Trial: 15486831
Drug: Tafenoquine, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine, 600 mg as a single dose (n=18)
Trial: 15486831
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (n=13)
Trial: 15486831
Drug: Primaquine base,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine base, 15 mg per day for 14 days (n=12)
Trial: 1734637
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 to 100 mg)
Trial: 1734637
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 to 100 mg) + Isosorbide dinitrate (ISDN) (10 mg)
Trial: 6469080
Drug: Pentagastrin infusion
RxNorm normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentagastrin infusion (0.15 micrograms/kg/h)
Trial: 6469080
Drug: Proglumide infusion
RxNorm normalized name: proglumide
DrugBank: Proglumide (DB13431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proglumide infusion (placebo control)
Trial: 27139058
Drug: Web-based guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based guided self-help intervention (cognitive-behavioral and problem-solving therapy supported by an online trainer; n=202)
Trial: 22786596
Drug: Stress management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress management therapy for MS (SMT‐MS)
Trial: 9445490
Drug: Allopurinol (ALLO;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (ALLO; 40 mg/kg)
Trial: 981327
Drug: Amitriptyline withdrawn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline withdrawn overtly to no medication
Trial: 29267300
Drug: 2 min
RxNorm normalized name: Accu-Clear 2 Minute Pregnancy Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 min CC with 8 min rest (Group A)
Trial: 29267300
Drug: 2 min
RxNorm normalized name: Accu-Clear 2 Minute Pregnancy Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 min CC with 4 min rest (Group B)
Trial: 29267300
Drug: 2 min
RxNorm normalized name: Accu-Clear 2 Minute Pregnancy Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 min CC with 6 min rest (Group C)
Trial: 29267300
Drug: 2 min
RxNorm normalized name: Accu-Clear 2 Minute Pregnancy Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 min CC with 8 min rest (Group D)
Trial: 25921965
Drug: Implantable cardioverter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantable cardioverter defibrillator (ICD)-only therapy
Trial: 19371931
Drug: Orchiopexy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orchiopexy combined with neoadjuvant GnRH therapy (1.2 mg/d nasal spray for 4 weeks)
Trial: 16750325
Drug: Once-daily chest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily chest wall irradiation (60 Gy in 2-Gy q.d. fractions)
Trial: 11728069
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (10 mg/kg body weight)
Trial: 8194141
Drug: Three-hourly subcutaneous
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-hourly subcutaneous bolus injections of morphine
Trial: 8194141
Drug: Microinfusion set
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microinfusion set for subcutaneous infusion
Trial: 2890268
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) 25 mg daily
Trial: 2890268
Drug: Furosemide (Lasix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (Lasix Retard, LR) 30 mg daily
Trial: 29341984
Drug: First dose
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First dose of RV1 (early administration)
Trial: 29341984
Drug: First dose
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First dose of RV1 (on-time administration)
Trial: 29341984
Drug: First dose
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First dose of RV1 (late administration)
Trial: 29341984
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of RV1 (early administration)
Trial: 29341984
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of RV1 (on-time administration)
Trial: 29341984
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of RV1 (late administration)
Trial: 22943627
Drug: Wellbeing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wellbeing therapy (WBT) based on personalized mobile technology
Trial: 16284462
Drug: lamivudine (3TC)
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lamivudine (3TC) - stavudine (d4T) - IDV (800 mg three times daily)
Trial: 16284462
Drug: Nevirapine (NVP)
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine (NVP) - d4T - IDV (1000 mg three times daily)
Trial: 10513804
Drug: Ciprofloxacin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (750 mg twice a day) for 12 months
Trial: 9816009
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (Control group)
Trial: 387329
Drug: Imipramine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (75 mg at bedtime)
Trial: 21330034
Drug: Comprehensive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive and intensive treatment of cardiovascular risk factors
Trial: 19084453
Drug: Inactivated trivalent
RxNorm normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated trivalent split virus influenza vaccine
Trial: 16968577
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of travoprost 0.004%/timolol 0.5% (T/T)
Trial: 16968577
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of latanoprost 0.005%/timolol 0.5% (L/T)
Trial: 15519437
Drug: Webster-Stratton parenting
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Webster-Stratton parenting program (16-hour weekly intervention)
Trial: 11049793
Drug: Paromomycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paromomycin (500 mg 4 times daily for 21 days)
Trial: 11049793
Drug: Paromomycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paromomycin (500 mg q.i.d. for an additional 21 days)
Trial: 7933789
Drug: Acebutolol, 400-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol, 400-800 mg/day for 12 weeks
Trial: 7933789
Drug: Propranolol, 80-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 80-160 mg/day for 12 weeks
Trial: 3739795
Drug: Multicomponent smoking
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent smoking relapse prevention treatment
Trial: 30448901
Drug: Gel with
RxNorm normalized name: GEL WITH PUMP (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel with 20% type III/80% type I collagen
Trial: 22645201
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment for 6 months
Trial: 16458133
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 325 mg/day
Trial: 15100915
Drug: Out-patient rehabilitation
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Out-patient rehabilitation (but received in-patient treatment)
Trial: 7507201
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose aprotinin
Trial: 2879872
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg norfloxacin
Trial: 2879872
Drug: TMP-SMZ (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP-SMZ (160 mg/800 mg)
Trial: 27283946
Drug: SYN-004 (75-750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYN-004 (75-750 mg single dose)
Trial: 27283946
Drug: SYN-004 (75-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYN-004 (75-300 mg multiple doses every 6 hours for 7 days)
Trial: 20023707
Drug: Early immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early immunization (3 months) with 7-valent pneumococcal vaccine
Trial: 20023707
Drug: Late immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late immunization (9 months) with 7-valent pneumococcal vaccine
Trial: 20023707
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of anti-pneumococcal antibodies functionality through opsonophagocytic assay
Trial: 12923723
Drug: Corticosteroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids and cytotoxic agents (alternating schedule for 6 months)
Trial: 12923723
Drug: Corticosteroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids and cytotoxic agents
Trial: 8299437
Drug: Jet-injected insulin
RxNorm normalized name: insulin degludec Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet-injected insulin
Trial: 8299437
Drug: Needle-injected insulin
RxNorm normalized name: insulin degludec Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle-injected insulin
Trial: 16400382
Drug: Adjuvant external
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant external beam radiotherapy (RTx) in addition to standard therapy
Trial: 16400382
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (thyroidectomy, ablative radioiodine therapy, and diagnostic 131I whole-body scintigraphy)
Trial: 16489696
Drug: Hyperfractionated radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiotherapy (74.4-79.2 Gy in 6.2-7 weeks, 1.2 Gy per fraction twice a day)
Trial: 16489696
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (Conventional, Hyperfractionated, Accelerated)
Trial: 16531613
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12